Here's everything you need to know before investing in Ami organics limited IPO (Ami organic IPO).

IPO Updates 02 September 2021 12:35:PM

Invest-in-ami-organics-IPO-with-GEPL-Capital Invest-in-ami-organics-IPO-with-GEPL-Capital

IPO of Ami Organics Limited will be live for subscription from September 1st, 2021 and this issue will last till September 3rd, 2021. Ami Organics' IPO price band has been set at Rs.603 to Rs.610 by the company's promoters. In the grey market, shares of the specialty chemical stock are currently available at a premium of Rs.50.

How to apply for Ami organics IPO?

With GEPL Capital’s IPO portal you can easily invest in ami organics as well as other active IPOs. We value your time that's why just click here and you'll be redirected to our IPO Investment Portal and with a few clicks, you'll be able to subscribe for the IPO of Ami organics.

More about Ami organic IPO:- 

Ami Organics Limited, founded in 2004, is a prominent specialty chemical manufacturer focused on research and development. Material for agrochemicals and fine chemicals, as well as Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, are manufactured by the company.

Over 450 pharmaceutical intermediates have been produced by the business in 17 therapeutic categories, including antiretroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It serves over 150 customers (including foreign customers) directly in India and in 25 countries across the world, including Europe, the United States, China, Israel, Japan, Latin America, and others. Domestic customers include Laurus Labs, Cadila Healthcare, and Cipla Ltd, while international customers include Organike s.r.l.a. Socio Unico, Fermion Oly, Medichem S.A., and Midas Pharma GmbH.

Ami Organics is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib, and Rivaroxaban. The Pharma Intermediates which they manufacture, find application in certain high-growth therapeutic areas including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, antiParkinson, anti-depressant, and anti-coagulant, commanding significant market share both in India and globally. They have developed and commercialized over 450 Pharma Intermediates for APIs across 17 key therapeutic areas since inception. Currently, Ami Organics has 8 process patent applications and 3 additional pending process patent applications for which applications were made recently, in March 2021.

Invest in Ami organics LTD.IPO with valid UPI ID  Apply Now

Details about IPO Ami organic:-

Opening Date Of IPO

Sep 1, 2021

Closing Date Of IPO

Sep 3, 2021

Face Value 

Rs.10 per equity share

Issue Type

Book Built Issue IPO

IPO Price

Rs.603 to Rs.610 per equity share

Market Lot


Minimum Order 


Listing BSE, NSE

Strengths of the Ami Organics IPO:-

  • Strong and diversified product portfolio ably supported by strong R&D and process chemistry skills.
  • Extensive geographical presence and diversified customer base with long-standing relationships
  • Diversification of product portfolio by strengthening R&D capabilities
  • a track record of consistent financial performance. 

COVID 19 Impact 

  • Based on Drug Class the Idiopathic Pulmonary Fibrosis Market is segmented by Nintedanib, Pirfenidone, and other drugs. Nintedanib is been used to treat Covid in many countries. It has the potential to block the development of lung fibrosis when initiated early enough to inhibit the activation of mesenchymal cells and the progression of virus-induced pulmonary fibrosis.
  • With the outbreak of Covid in 2020 and the second wave hitting in 2021, experts estimate that covid is expected to last for a couple of more years and the medication for the same is expected to witness substantial growth in the near future.
  • With Nintedanib gaining prominence in treating lung fibrosis, it will have good market traction. Ami Organics is the only supplier to the originator – Boehringer Ingelheim, for key intermediates for producing Nintedanib.

Financial Snapshot of the company:- 

Valuation & Recommendation:

By pursuing strategic acquisitions including the recently concluded acquisition of the business of GOL, they will add to their capabilities and technical expertise or enter into partnerships to strengthen their product infrastructure and overall manufacturing capabilities in the specialty chemicals sector.

They intend to develop, test and manufacture new products meeting regulatory standards subsequent to receipt of requisite regulatory approvals from the relevant authorities in India and overseas and make investments on an ongoing basis in new product launches and research and development for future products.

They also intend to invest in the development of products that are used in the manufacture of APIs being used in formulations whose patents are expiring. We recommend a subscribe rating to the issue

Invest in Ami organics LTD.IPO with valid UPI ID  Apply Now

To apply for this IPO visit here and easily apply with UPI. Be the client of one of the most trusted stock-broker in India with a very few steps Click Here

Popular Blogs


5 best stocks to buy in India for short term in 2022.

.imgsize { height: 28px; width: 106px; } Want to make a short-term investment in the stock market to earn double-digit returns on your investment? Than this ...

Read More

Peak Margin Rule : What changes in new phase for peak margin penalty

With reference to the SEBI circular dated 20th July 2020, Peak Margin has been introduced in the Equity, Commodity & Currency segment from 1st December 2020.  W.e.f  1st June 2021, there ...

Read More

Tata Perpetual Bond, a fixed income opportunity?

The private placement of Tata Motors comes with a coupon of 9.10 percent. The private placement of Tata Motors Finance Ltd (TMFL) comes with a coupon of 9.10 percent. The private placement of ...

Read More
Wildcard SSL